Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 1351 - 1375 of 2538 in total
TASO-001 is a transforming growth factor (TGF)-beta 2 specific antisense oligodeoxynucleotide.
Investigational
Investigational
EXOB-001 consists of extracellular vesicles derived from cultured human umbilical cord mesenchymal stromal cells.
Investigational
CALY-002 is a humanized monoclonal antibody targeting interleukin-15.
Investigational
Investigational
ABBV-011 is an antibody-drug conjugate of humanized, cysteine-engineered IgG1 monoclonal antibody targeting seizure-related 6 homolog conjugated to N-acetyl-gamma-calicheamicin.
Investigational
Investigational
Experimental
Experimental
Experimental
Experimental
Experimental
TG100801 is a topically applied kinase inhibitor in macular degeneration patients. It is administered noninvasively as an eye drop and is designed to suppress VEGF mediated leakage and additional kinase targets associated with inflammation, edema, and angiogenesis which are the pathological hallmarks of AMD and other back of the eye...
Investigational
CPG 10101 is a synthetic oligodeoxynucleotide (ODN) in clinical trials. It is a toll-like receptor 9 (TLR9) agonist with antiviral and immunomodulatory properties that could potentially influence chronic infection with HCV.
Investigational
Matched Description: … It is a toll-like receptor 9 (TLR9) agonist with antiviral and immunomodulatory properties that could …
KB109 is a prebiotic to feed healthy bacteria for them to to outcompete multi-drug resistance organisms.
Investigational
P-BCMA-101 is an autologous CAR-T therapy developed using Poseida’s piggyBac platform technology.
Investigational
AP103 is a non-viral gene therapy that uses a delivery vector, HPAE (Highly Branched Poly β-Amino Ester), to deliver the correct collagen VII gene into skin cells.
Investigational
INBRX-101 is a recombinant human alpha-1 antitrypsin (AAT)-Fc fusion protein.
Investigational
Experimental
Matched Name: … 3-[(9H-fluoren-9-ylideneamino)oxy]propanoic acid …
Matched Iupac: … 3-{[(9H-fluoren-9-ylidene)amino]oxy}propanoic acid …
Experimental
V1003 is an intranasal formulation of buprenorphine, an opiate analgesic, for the management of post-operative pain in hospital and home settings. Buprenorphine is a well-known analgesic and the intranasal formulation has the potential to provide a convenient alternative to other treatments, allowing patients to manage their post-operative pain both prior...
Investigational
OBE101 is a new weight loss drug developed by Obecure Ltd. It is a new formulation that is based on the vertigo medication, Betahistine. Obecure is repurposing betahistine, which is an H1 receptor agonist and partial H3 receptor antagonist for the treatment of obese individuals and for other weight management...
Investigational
CAD106 is an immunotherapeutic product in development for the treatment of Alzheimer's disease. It is designed to induce antibodies against the beta-amyloid-protein that inhibit the formation of plaques in the brain of Alzheimer's disease patients.
Investigational
Investigational
IMM-101 is a heat-inactivated immune-activating mycobacterial product. It has shown to be safe and well tolerated to complement conventional cancer therapy for patients with melanoma and pancreatic ductal adenocarcinoma [PMID: 21930686; PMID: 30107850; PMID: 27599039]. Studies with IMM-101 showed the vaccine’s ability to stimulate cancer patients’ immune systems to help...
Investigational
Displaying drugs 1351 - 1375 of 2538 in total